MRNA250103P50000
- 7.75
- -0.75-8.82%
Moderna Newsroom
Moderna (MRNA) Rises But Trails Market: What Investors Should Know
Moderna Options Spot-On: On January 3rd, 117.68K Contracts Were Traded, With 657.56K Open Interest
Unusual Options Activity: PG, DAL and Others Attract Market Bets, PG V/OI Ratio Reaches 133.3
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
The S&P 500's 10 Worst Performing Stocks in 2023 Fell Again in 2024
Best and Worst Performing S&P 500 Stocks in a Rosy Year for Index
Santa Claus Came Without Rallying the Troops | Live Stock
Moderna Options Spot-On: On January 2nd, 112.55K Contracts Were Traded, With 646.17K Open Interest
These Battered S&P 500 Stocks Could Be Ripe for a Turnaround in 2025
Why Moderna Inc. (MRNA) Is Skyrocketing
Equity Markets Fall Intraday as 2024 Draws to Close
Peering Into Moderna's Recent Short Interest
These Stocks Are Moving the Most Today: Super Micro, Moderna, Nvidia, MicroStrategy, Palantir, VeriSign, Sangamo, and More -- Barrons.com
This Biotech Is One of the S&P 500's Worst Performers. It Looks Too Cheap. -- Barrons.com
Moderna Options Spot-On: On December 30th, 58,168 Contracts Were Traded, With 684.76K Open Interest
Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock
Morgan Stanley: Personalized cancer vaccines and ADCs will become the main catalysts in the oncology treatment Industry by 2025.
Morgan Stanley stated in a recent research report that personalized cancer vaccines and antibody-drug conjugates (ADCs) will become one of the major innovations in cancer biotechnology next year.
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Weekly Buzz: So far, Santa is Letting us Down